SUMM Summit Therapeutics Plc

 
TIDMSUMM 
 
   Summit Therapeutics plc 
 
   ("Summit Therapeutics" or the "Company") 
 
   AIM Delisting Reminder 
 
   Oxford, UK, and Cambridge, MA, US, 11 February 2020 - Summit 
Therapeutics (AIM: SUMM, NASDAQ: SMMT), a leader in antibiotic 
innovation, issues a reminder that, as previously announced and pursuant 
to AIM Rule 41, the Company's ordinary shares of one penny nominal value 
("Ordinary Shares") will cease to be admitted to trading on AIM at 7.00 
am on 24 February 2020. Accordingly, the final day of trading on AIM of 
the Company's Ordinary Shares will be 21 February 2020. 
 
   The Company's American Depositary Shares ("ADSs") will remain listed on 
the Nasdaq Global Market and all public trading of shares in the Company 
after that date will take place on that exchange; one ADS is represented 
by five Ordinary Shares. Thereafter, Ordinary Shares will continue to be 
capable of being held and transferred in certificated form, but there 
will be no public market in the UK on which the shareholders of the 
Company will be able to trade Ordinary Shares. 
 
   Shareholder are able to convert Ordinary Shares into ADSs and by doing, 
are able to trade such ADSs on Nasdaq. Further information can be found 
on the Company's website at 
https://www.globenewswire.com/Tracker?data=AGgU9xWMPIIp2PyRKw9V14P5mZd4Rhd7ifPIIOQKOkqYsiTzpWQNNJ3pipCN_IZwnoAKie-x49moRt6rzXwcL765pSaaolZu4Xi5rrnYI1TseBdhW28O8cVOYH3l7s777v1nYFbI87QK58Pjdam0rF03FPcG_WPuMvLbskTVwpA= 
https://www.summitplc.com/investors/investor-centre/ under the heading 
"AIM Delisting FAQs". 
 
   About Summit Therapeutics 
 
   Summit Therapeutics is a leader in antibiotic innovation. Our new 
mechanism antibiotics are designed to become the new standards of care 
for the benefit of patients and create value for payors and healthcare 
providers. We are currently developing new mechanism antibiotics to 
treat infections caused by C. difficile, Enterobacteriaceae and N. 
gonorrhoeae, and are using our proprietary Discuva Platform to expand 
our pipeline. For more information, visit www.summitplc.com and follow 
us on Twitter @summitplc. 
 
   For more information, please contact: 
 
 
 
 
Summit 
Glyn Edwards / Richard Pye (UK office)              Tel:    44 (0)1235 443 951 
Michelle Avery (US office)                                     +1 617 225 4455 
 
Cairn Financial Advisers LLP (Nominated Adviser)    Tel:   +44 (0)20 7213 0880 
Liam Murray / Tony Rawlinson / Ludovico Lazzaretti 
 
 
 
   -END- 
 
 
 
 

(END) Dow Jones Newswires

February 11, 2020 05:00 ET (10:00 GMT)

Summit Therapeutics (LSE:SUMM)
Historical Stock Chart
From Oct 2024 to Nov 2024

Summit Therapeutics (LSE:SUMM)
Historical Stock Chart
From Nov 2023 to Nov 2024